scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Acquired by King Luther Capital Management Corp

King Luther Capital Management Corp boosted its position in shares of scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) by 28.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,857,910 shares of the company's stock after buying an additional 632,120 shares during the period. King Luther Capital Management Corp owned 5.71% of scPharmaceuticals worth $10,117,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SCPH. Rhumbline Advisers grew its holdings in shares of scPharmaceuticals by 20.1% during the fourth quarter. Rhumbline Advisers now owns 42,554 shares of the company's stock worth $151,000 after buying an additional 7,112 shares during the last quarter. Rubric Capital Management LP lifted its position in scPharmaceuticals by 35.5% during the 3rd quarter. Rubric Capital Management LP now owns 4,775,000 shares of the company's stock worth $21,774,000 after acquiring an additional 1,250,000 shares during the period. Sanctuary Advisors LLC acquired a new position in shares of scPharmaceuticals in the third quarter valued at approximately $75,000. XTX Topco Ltd purchased a new stake in shares of scPharmaceuticals during the third quarter worth approximately $124,000. Finally, Suvretta Capital Management LLC purchased a new stake in shares of scPharmaceuticals during the third quarter worth approximately $9,343,000. Hedge funds and other institutional investors own 89.52% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a "buy" rating and issued a $18.00 target price on shares of scPharmaceuticals in a research note on Monday, March 3rd.

Remove Ads

scPharmaceuticals Stock Performance

NASDAQ SCPH traded up $0.04 on Friday, hitting $3.03. 204,832 shares of the company's stock were exchanged, compared to its average volume of 321,923. The firm has a market cap of $151.62 million, a price-to-earnings ratio of -1.59 and a beta of 0.40. The firm's 50-day moving average price is $3.33 and its two-hundred day moving average price is $3.87. scPharmaceuticals Inc. has a fifty-two week low of $2.75 and a fifty-two week high of $6.20. The company has a debt-to-equity ratio of 1.66, a current ratio of 8.08 and a quick ratio of 6.89.

scPharmaceuticals Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.